Infinity Pharmaceuticals, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2001-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.infi.com
Safety Study of IPI-504 in Patients With Relapsed and Relapsed Refractory Multiple Myeloma
Phase 1
Completed
- Conditions
- Multiple Myeloma
- First Posted Date
- 2005-06-07
- Last Posted Date
- 2008-05-20
- Lead Sponsor
- Infinity Pharmaceuticals, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT00113204
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Hackensack University Medical Center The David Jurist Research Center, Hackensack, New Jersey, United States
🇺🇸Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
© Copyright 2025. All Rights Reserved by MedPath